electroCore Expands Intellectual Property Portfolio
ROCKAWAY, N.J., Jan. 09, 2024 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to systems and methods for treating post-traumatic stress disorder (PTSD).
Related news for (ECOR)
- electroCore Completes Acquisition of NeuroMetrix, Gaining Access to its Quell Platform, Creating Significant Player in Non-Invasive Bioelectronic Technologies
- electroCore’s Truvaga™ Now Works with the Apple Health app
- electroCore Named One of The Americas’ Fastest Growing Companies by the Financial Times
- electroCore Extends VA Contract for Five Years
- electroCore Announces Full Year 2024 Financial Results